http://jnci.oxfordjournals.org/content/98/22/1655.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/98/22/1655" />
      <meta content="/jnci/98/22/1655.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments"
            name="DC.Title" />
      <meta content="10.1093/jnci/djj443" name="DC.Identifier" />
      <meta content="2006-11-15" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Maria Kyrgiou" name="DC.Contributor" />
      <meta content="Georgia Salanti" name="DC.Contributor" />
      <meta content="Nicholas Pavlidis" name="DC.Contributor" />
      <meta content="Evangelos Paraskevaidis" name="DC.Contributor" />
      <meta content="John P. A. Ioannidis" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Maria Kyrgiou" />
      <meta name="citation_author" content="Georgia Salanti" />
      <meta name="citation_author" content="Nicholas Pavlidis" />
      <meta name="citation_author" content="Evangelos Paraskevaidis" />
      <meta name="citation_author" content="John P. A. Ioannidis" />
      <meta content="Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments"
            name="citation_title" />
      <meta content="11/15/2006" name="citation_date" />
      <meta content="98" name="citation_volume" />
      <meta content="22" name="citation_issue" />
      <meta content="1655" name="citation_firstpage" />
      <meta content="1663" name="citation_lastpage" />
      <meta content="98/22/1655" name="citation_id" />
      <meta content="98/22/1655" name="citation_id_from_sass_path" />
      <meta content="jnci;98/22/1655" name="citation_mjid" />
      <meta content="10.1093/jnci/djj443" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/98/22/1655.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/22/1655.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/22/1655.full.pdf"
            name="citation_pdf_url" />
      <meta content="http://jnci.oxfordjournals.org/content/98/22/1655"
            name="citation_public_url" />
      <meta content="17105988" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/98/22/1647.short" rel="prev" />
      <link href="/content/98/22/1664.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d28417632e1">var callbackToken='537AFA168D60A21';</script><script type="text/javascript" id="session-d28417632e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:14:17.5-07:00';
            var gSessionId = 'yGfzsMXrKz81VzyLBAQtbg';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djj443");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("15 November 2006");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F98%2F22%2F1655.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/98/22.toc">
                  <span xmlns="" class="volume-value">Volume 98</span>
                  <span xmlns="" class="issue-value"> Issue 22</span></a></li>
            <li>Pp. <span class="slug-pages">
                  1655-1663.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/98/22/1655.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Maria+Kyrgiou&amp;sortspec=date&amp;submit=Submit">Maria Kyrgiou</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Georgia+Salanti&amp;sortspec=date&amp;submit=Submit">Georgia Salanti</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Nicholas+Pavlidis&amp;sortspec=date&amp;submit=Submit">Nicholas Pavlidis</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Evangelos+Paraskevaidis&amp;sortspec=date&amp;submit=Submit">Evangelos Paraskevaidis</a></span> and 
                     </li>
                     <li class="last" id="contrib-5"><span class="name"><a class="name-search"
                              href="/search?author1=John+P.+A.+Ioannidis&amp;sortspec=date&amp;submit=Submit">John P. A. Ioannidis</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><em>Affiliations of authors:</em> Department of Obstetrics and Gynaecology, Hammersmith Hospital, Queen Charlotte's and Chelsea Hospital, London, U.K. (MK);
                           Department of Obstetrics and Gynaecology, University Hospital of Ioannina, Ioannina, Greece (MK, EP); Medical Research Council,
                           Biostatistics Unit, Cambridge, U.K. (GS); Division of Medical Oncology, University of Ioannina School of Medicine, Ioannina,
                           Greece (NP); Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina
                           School of Medicine, Ioannina, Greece (JPAI); Biomedical Research Institute, Foundation for Research and Technology-Hellas,
                           Ioannina, Greece (JPAI); Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts University
                           School of Medicine, Boston, MA (JPAI)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><em>Correspondence to:</em> John P. A. Ioannidis, MD, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, University Campus,
                        Ioannina 45110, Greece (e-mail: <span class="em-link"><span class="em-addr">jioannid{at}cc.uoi.gr</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2006-06-07"><span class="received-label">Received </span>June 7, 2006.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2006-08-29"><span class="rev-recd-label">Revision received </span>August 29, 2006.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2006-09-21"><span class="accepted-label">Accepted </span>September 21, 2006.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-1" title="METHODS" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <p id="p-1"><em>Background:</em> Numerous randomized trials have compared different chemotherapy regimens in women with ovarian cancer. Although ovarian cancer
                     survival has improved in recent years, the magnitude of these incremental benefits across diverse regimens is unclear. <em>Methods:</em> We used multiple-treatment meta-analysis methodology to combine information from direct and indirect comparisons of all chemotherapy
                     regimens used in randomized trials of ovarian cancer in the last 40 years. Chemotherapy was categorized by the use or not
                     of platinum and/or taxanes, combinations of agents, and intraperitoneal administration. Monte Carlo simulations were used
                     to determine which regimen most improved survival. Analyses of trials that examined first- and second-line treatments were
                     also performed separately. <em>Results:</em> We found 198 trials (N = 38 440 women) involving 120 different chemotherapy regimens published in 1971–2006. Eighty-two trials
                     compared different types of chemotherapy, among which 60 had usable survival information (N = 15 609 women). Monte Carlo simulations
                     showed a 92% probability that the regimen that best prolonged survival is a platinum and taxane combination with intraperitoneal
                     administration; this regimen resulted in a 55% relative risk reduction (95% confidence interval [CI] = 39% to 67%) for mortality
                     as compared with nonintraperitoneal monotherapy using neither platinum nor taxane. Against that same monotherapy comparator,
                     platinum-based combinations with and without intraperitoneal administration achieved 40% (95% CI = 21% to 54%) and 30% (95%
                     CI = 20% to 38%) relative risk reductions for mortality, respectively, and combinations involving platinum and taxane without
                     intraperitoneal administration achieved a 42% (95% CI = 31% to 51%) relative risk reduction. Results were similar when analyses
                     were limited to first-line treatment. Data on second-line treatment were consistent with the superiority of platinum and taxane
                     combinations. <em>Conclusions:</em> Distinct incremental improvements in survival have been achieved for ovarian cancer chemotherapy over time, with the possibility
                     to achieve a doubling or more of time to mortality with platinum and taxane combinations, especially when intraperitoneal
                     administration is used.
                  </p>
                  
               </div>
               <p id="p-2">Ovarian cancer is a major cause of death worldwide, and it is especially prevalent in developed countries <em>(<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>–<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>)</em>. The overall 5-year survival rate is poor, at approximately 30% for women older than 65 years <em>(<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>)</em>. Typically, primary treatment consists of surgery and some form of chemotherapy <em>(<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>)</em>. Alkylating agents were used initially, with poor results, but platinum-based chemotherapy has improved outcomes in the last
                  25 years <em>(<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>–<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>).</em> In the last 10 years, evidence has also started to accumulate that taxanes and their combination with platinum agents may
                  further improve outcomes <em>(<a id="xref-ref-7-2" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>–<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>)</em>. Data from recent studies also suggest that additional benefits are achieved by intraperitoneal chemotherapy <em>(<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>)</em>.
               </p>
               <p id="p-3">Although there is wide consensus that chemotherapy prolongs survival in women with epithelial ovarian cancer, the exact magnitude
                  of the survival benefits with various regimens is unclear. Approximately, 200 randomized trials comparing different chemotherapy
                  regimens for ovarian cancer have been published. Because newer or more intensive regimens also have higher toxicity, it is
                  important to quantify the incremental survival benefits, if any, conferred by each type of chemotherapy as compared with older
                  regimens.
               </p>
               <p id="p-4">Here we performed an overview of all randomized trials comparing chemotherapy regimens in patients with ovarian cancer. We
                  aimed to present the evolution of the randomized evidence over time as newer regimens were tested. We examined whether specific
                  regimens are superior to others and evaluated the magnitude of the benefit. Given the wide spectrum of comparisons available,
                  we used multiple-treatment meta-analysis <em>(<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>–<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>)</em>. This method allowed us to integrate data from both direct and indirect comparisons of diverse regimens.
               </p>
               <div class="section" id="sec-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-5" title="RESULTS" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>M<span class="sc">ETHODS</span></h2>
                  
                  
                  <h3>Search Strategy and Eligibility Criteria</h3>
                  
                  <p id="p-5">We searched MEDLINE, EMBASE, and the Central Registry of Controlled Trials of the Cochrane Library (1965 until January 2006).
                     The search strategy used “ovarian cancer or neoplasia” and “chemotherapy” with an array of terms suggestive of randomized
                     trials <em>(<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>)</em>. The full strategy is available on request. We also perused the references of retrieved articles and of previous meta-analyses.
                     Additional cross-searches were performed in MEDLINE using the names of investigators who were the lead authors of at least
                     one eligible trial. In addition, we hand-searched several years of the journals with the highest number of electronically
                     identified trials <em>(<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>)</em>.
                  </p>
                  
                  <p id="p-6">We considered all randomized controlled trials published in English, German, French, or Italian that compared at least two
                     arms of different chemotherapy regimens (different agents and/or schedules) in at least five patients with ovarian cancer.
                     Trials were included regardless of stage and line of treatment. Trials with at least three arms were included if at least
                     two arms addressed an eligible comparison; noneligible arms were excluded. We excluded meeting abstracts; nonrandomized trials
                     and pseudorandomized trials with alternate allocation of subjects; data on other malignancies or nonepithelial ovarian cancer;
                     trials comparing radiotherapy, immunotherapy, hormonal therapy, and gene therapy (unless the above regimens were the same
                     in all compared arms and the difference between arms pertained to the chemotherapeutic regimens only); and comparisons of
                     chemotherapy against no chemotherapy (best supportive care). In cases of overlap or duplicate reports, we retained only the
                     survival data with the maximal follow-up.
                  </p>
                  
                  
                  
                  <h3>Data Extraction</h3>
                  
                  <p id="p-7">From each eligible trial, we recorded the first author, publication year, journal, country or countries of the investigators,
                     sample size (randomized and considered eligible for survival analyses [total and per arm]), regimens compared, the line of
                     chemotherapy, previous chemotherapy, stage(s) of the disease, and percentage of patients with performance status 2 or worse
                     (Karnofsky score ≤ 70) per arm.
                  </p>
                  
                  <p id="p-8">The type of chemotherapy regimen was categorized according to whether it involved platinum, taxane, both, or neither; used
                     a combination of agents or monotherapy; and used intraperitoneal administration of any agents or not. Theoretically, this
                     categorization gives rise to 14 possible types of chemotherapy, not all of which have necessarily been tested in trials.
                  </p>
                  
                  <p id="p-9">For each trial, we recorded the median survival and the number of deaths per arm, if available, and whether there was a statistically
                     significant difference in survival between the compared arms (two-tailed <em>P</em>&lt;.05). When several analyses were reported, we preferred the log-rank test results over other statistics and unadjusted analyses
                     over adjusted analyses. For trials including at least two arms, statistical significance was assessed for an analysis considering
                     all arms.
                  </p>
                  
                  <p id="p-10">For trials that compared at least two different types of chemotherapy regimens, we also extracted or estimated the hazard
                     ratio (HR) and its variance. We used the reported hazard ratios and 95% confidence intervals (CIs) from Cox regression models.
                     Unadjusted hazard ratios were preferred over multivariable ones. For trials that did not provide this information on hazard
                     ratios and their uncertainty, we imputed these data by using the number of events (<em>E</em><sub>1</sub>, <em>E</em><sub>2</sub>) and patients (<em>T</em><sub>1</sub>, <em>T</em><sub>2</sub>) in each arm and the presented log-rank <em>P</em> value. We estimated the variance by the formula (<em>T</em><sub>1</sub> + <em>T</em><sub>2</sub>)<sup>2</sup>/[(<em>E</em><sub>1</sub> + <em>E</em><sub>2</sub>)<em>T</em><sub>1</sub><em>T</em><sub>2</sub>] and then estimated the natural logarithm of the hazard ratio such that it would have the <em>P</em> value denoted by the log-rank test <em>(<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>)</em>. If the log-rank <em>P</em> value was also not available, we estimated the hazard ratio as the inverse of the ratio of the median survival times from
                     the presented Kaplan–Meier curves assuming exponential survival curves and proportional hazards.
                  </p>
                  
                  <p id="p-11">Data were extracted independently by two investigators (MK and JPAI). Discrepancies were discussed to reach consensus.</p>
                  
                  
                  
                  <h3>Statistical Analyses</h3>
                  
                  <p id="p-12">We generated descriptive statistics for trial and study population characteristics across all eligible trials. We described
                     the types of comparisons and how these had evolved over time.
                  </p>
                  
                  <p id="p-13">We conducted a series of meta-analyses summarizing the log hazard ratios for each comparison of two different types of treatment
                     applying random effects <em>(<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>)</em>. Between-study heterogeneity was estimated using the <em>I</em><sup>2</sup> statistic <em>(<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a>)</em>.
                  </p>
                  
                  <p id="p-14">Multiple-treatment meta-analysis is a method of synthesizing information from a network of trials <em>(<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>)</em>. Trials comparing treatments A and B provide direct evidence on the relative effect size <span class="inline-formula" id="inline-formula-1"><img class="math tex" alt="Formula" src="1655/embed/tex-math-1.gif" /></span> (here the log hazard ratio). However, it is possible that indirect information may also be available through a common comparator,
                     e.g., treatment C. Studies comparing A versus B, B versus C, and C versus A form a simple network. Indirect evidence about
                     the effectiveness of A versus B is given by <span class="inline-formula" id="inline-formula-2"><img class="math tex" alt="Formula" src="1655/embed/tex-math-2.gif" /></span> The combination of the direct and indirect estimates <span class="inline-formula" id="inline-formula-3"><img class="math tex" alt="Formula" src="1655/embed/tex-math-3.gif" /></span> and <span class="inline-formula" id="inline-formula-4"><img class="math tex" alt="Formula" src="1655/embed/tex-math-4.gif" /></span> into a single effect size can increase precision while randomization is respected <em>(<a id="xref-ref-27-2" class="xref-bibr" href="#ref-27">27</a>,<a id="xref-ref-28-2" class="xref-bibr" href="#ref-28">28</a>)</em>. The combination of direct and indirect evidence for any given treatment comparison can be extended when ranking more than
                     three types of treatments according to their effectiveness: every study contributes evidence about a subset of these treatments.
                  </p>
                  
                  <p id="p-15">Multiple-treatment meta-analysis should be used with caution, and the underlying assumptions of the exchangeability of studies
                     across the entire network should be investigated carefully <em>(<a id="xref-ref-19-2" class="xref-bibr" href="#ref-19">19</a>,<a id="xref-ref-28-3" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>)</em>. Exchangeability means that characteristics of the trials would not greatly modify the magnitude of the treatment effects.
                     Exchangeability was tested by examining heterogeneity and incoherence. Joint analysis of treatments can be misleading if the
                     network is substantially incoherent, i.e., if there is disagreement between indirect and direct estimates <span class="inline-formula" id="inline-formula-5"><img class="math tex" alt="Formula" src="1655/embed/tex-math-5.gif" /></span> and <span class="inline-formula" id="inline-formula-6"><img class="math tex" alt="Formula" src="1655/embed/tex-math-6.gif" /></span></p>
                  
                  <p id="p-16">We performed multiple-treatment meta-analysis with a linear mixed-effects model. Incoherence was taken into account by applying
                     a model that suggests two levels in random effects—one at the level of general comparison being made (e.g., A versus B) and
                     the other at the level of each specific study <em>(<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>)</em>. The comparison-specific effects follow a distribution with zero mean and standard deviation that reflects the incoherence
                     of the network.
                  </p>
                  
                  <p id="p-17">One set of multiple-treatment meta-analysis addressed all eligible trials comparing different types of chemotherapy. However,
                     line of treatment may be an important confounder. Therefore, we also considered two separate analyses: one that included only
                     trials that addressed first-line treatment and another that included trials that addressed second-line therapy.
                  </p>
                  
                  <p id="p-18">Analyses were conducted in R, version 2.2.1 (R Institute, Vienna, Austria) using lme functions. We also estimated the probability
                     for each type of treatment to be the best at prolonging survival, given the results of the multiple-treatment meta-analysis,
                     using Monte Carlo simulations in WinBUGS, version 1.4 (MRC Biostatistics Unit, Cambridge, U.K., <a href="http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml">http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml</a>). A major advantage of working within a Bayesian framework is that probabilistic statements about the effectiveness of the
                     different treatments can be made. The prior assumption is that all treatments are equally likely to be the best. For example,
                     the probability of a treatment <em>T</em><sub>i</sub> to be the best out of N treatments can be calculated as the posterior probability <em>P</em>(Rank(<em>T</em><sub>i</sub>) = N). In WinBUGS code, P.most.effective&lt;-equals(rank(mean[],i),N).
                  </p>
                  
                  
               </div>
               <div class="section" id="sec-5">
                  <div class="section-nav"><a href="#sec-1" title="METHODS" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-10" title="DISCUSSION" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>R<span class="sc">ESULTS</span></h2>
                  
                  
                  <h3>Eligible Trials</h3>
                  
                  <p id="p-19">The electronic searches yielded 4653 items from MEDLINE, 3276 from EMBASE, and 1916 from Cochrane Central. Of these, 727 potentially
                     eligible articles were scrutinized. We excluded 529 reports that did not meet eligibility criteria (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>), leaving 198 trials that qualified for the overview.
                     
                  </p>
                  <div id="F1" class="fig pos-float odd">
                     <div class="fig-inline"><a href="1655/F1.expansion.html"><img alt="Fig. 1." src="1655/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="1655/F1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1655/F1.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/98/22/1655/F1">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Fig. 1.</strong></span> 
                        <p id="p-20" class="first-child">Flow chart for included and excluded trials. MTM = multiple-treatment meta-analysis.</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-21">The 198 trials (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>; Supplementary Data, available at: <a href="http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22">http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22</a>) had been published from 1971 to January 2006. The median sample size was 103 patients (interquartile range = 53–234 patients).
                     Only four trials had more than 1000 subjects; 18 had more than 500 subjects. A total of 38 440 subjects were randomly assigned
                     across 421 arms, and 36 029 subjects were included in survival analyses. In most reports, no previous chemotherapy had been
                     given. There was considerable variability in the percentage of patients with poor performance status, but the percentage of
                     such enrolled patients decreased over time (−6% per decade, <em>P</em> = .003). In only two trials did the majority of patients have stage I disease. Most trials were done in the United States
                     and in Europe (<a id="xref-table-wrap-1-2" class="xref-table" href="#T1">Table 1</a>). Only 5% of the studies included one or more intraperitoneally administered agents.
                     
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1655/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1655/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 1.</strong> </span> 
                        <p id="p-22" class="first-child">Characteristics of the eligible trials</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-26">Eighty-two of the 198 trials compared different types of regimens according to our a priori categorization. Overall, this
                     set of 82 trials had a similar profile as the total dataset of 198 trials (<a id="xref-table-wrap-1-3" class="xref-table" href="#T1">Table 1</a>).
                  </p>
                  
                  
                  
                  <h3>Compared Chemotherapy Regimens</h3>
                  
                  <p id="p-27">A total of 120 different regimens were tested in the 198 trials. Only six monotherapies and 15 combinations of different agents
                     had been tested in at least four trial arms each (Supplementary Table 1, available at: <a href="http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22">http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22</a>). Moreover, doses and schedules of the same regimen often differed across trials. The most commonly used regimen—cisplatin,
                     cyclophosphamide, and doxorubicin—had been used in 34 arms, followed by cisplatin and cyclophosphamide (n = 33 arms), paclitaxel
                     (n = 24), cisplatin (n = 23), carboplatin (n = 21), and carboplatin and paclitaxel (n = 19). Nonplatinum, nontaxane regimens
                     dominated trials published in the 1970s, platinum-based combinations prevailed in the 1980s and 1990s, and combinations including
                     platinum and taxane are the most common regimens used recently (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a>).
                     
                  </p>
                  <div class="table pos-float" id="T2">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1655/T2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1655/T2.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 2.</strong> </span> 
                        <p id="p-28" class="first-child">Number of arms per decade that used each regimen (% per decade)*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-30">Of 116 trials that compared only regimens of the same type, only six found statistically significant differences in survival
                     (Supplementary Table 2, available at: <a href="http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22">http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22</a>). The percentage (5%) is not beyond what is expected by chance. In two trials with statistically significant differences,
                     the median survival difference between the compared arms was less than 2 months. Three trials showed differences among different
                     regimens involving platinum, but there were 59 trials comparing different platinum-based regimens. One small trial found differences
                     of borderline statistical significance between two regimens involving neither platinum nor taxanes among 29 trials that compared
                     such regimens. Therefore, although minor differences between regimens using the same classes of drugs cannot be totally excluded,
                     these differences would probably be very small overall, if not chance findings.
                  </p>
                  
                  
                  
                  <h3>Comparisons of Different Types of Regimens</h3>
                  
                  <p id="p-31">Of the 82 trials comparing different types of regimens, 60 had survival data (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>; Supplementary Table 3 and Supplementary Fig. 1, available at: <a href="http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22">http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22</a>), and these were included in quantitative syntheses (16 478 randomly assigned subjects, 15 609 in survival analyses). The
                     other 22 trials (1380 randomly assigned subjects) were typically phase 1/2 or phase 2 trials with no usable survival data.
                     
                  </p>
                  <div class="table pos-float" id="T3">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1655/T3.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1655/T3.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 3.</strong> </span> 
                        <p id="p-32" class="first-child">Trials included with survival data in the multiple-treatment meta-analysis</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-35">We first made pairwise comparisons of regimens from the 60 trials based on direct evidence only (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>). Heterogeneity (<em>I</em><sup>2</sup> &gt; 35%) was found only for the comparison of platinum-based combinations versus platinum and taxane–based combinations (<em>I</em><sup>2</sup> = 70%, four studies), among which three trials using a cisplatin background found a statistically significant survival benefit
                     for the addition of taxane, whereas the trial with a carboplatin background found no such benefit. Direct comparisons showed
                     that platinum monotherapy was statistically significantly better than monotherapy with a nonplatinum, nontaxane agent, and
                     a platinum-based combination was better than monotherapy or combinations involving neither platinum nor taxanes (relative
                     risk reduction of mortality [RRR] = 37%, 22%, and 23%, respectively). Moreover, combinations involving neither platinum nor
                     taxane were better than monotherapy with such agents (RRR = 17%), platinum and taxane–based combinations were better than
                     platinum-based combinations (RRR = 21%), and intraperitoneal administration improved survival with platinum and taxane–based
                     combinations (RRR = 21%).
                     
                  </p>
                  <div id="F2" class="fig pos-float odd">
                     <div class="fig-inline"><a href="1655/F2.expansion.html"><img alt="Fig. 2." src="1655/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="1655/F2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1655/F2.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/98/22/1655/F2">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Fig. 2.</strong></span> 
                        <p id="p-36" class="first-child">Hazard ratios (and 95% confidence intervals) for survival in meta-analyses of direct comparisons between various types of
                           chemotherapy. Summary estimates are shown by <strong>diamonds</strong>. Size of symbols is proportional to the inverse variance of the estimate. <strong>A</strong>) Comparisons addressing at least one regimen involving platinum. <strong>B</strong>) Other comparisons. The names of the first author for each study are shown on the <strong>left side</strong>.
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
                  
                  <h3>Multiple-Treatment Meta-analysis</h3>
                  
                  <p id="p-37">We next performed multiple-treatment meta-analysis of all 60 trials with survival data (<a id="xref-table-wrap-4-1" class="xref-table" href="#T4">Table 4</a>). The combination of nonplatinum and nontaxane agents (not given intraperitoneally) was associated with a small decrease
                     in mortality risk (RRR = 13%) compared with monotherapy with a nonplatinum, nontaxane agent. Platinum monotherapy (RRR = 32%)
                     or platinum-based combination therapy with (RRR = 40%, 95% CI = 21% to 54%) or without (RRR = 30%, 95% CI = 20% to 38%) intraperitoneal
                     administration was associated with more prominent statistically significant survival benefits than nonplatinum agents. Data
                     on taxane-based regimens were sparse, and no formally statistically significant survival benefits were found. Combinations
                     involving both platinum and taxane achieved the most impressive benefits (when intraperitoneal administration was involved,
                     RRR = 55%, 95% CI = 39% to 67%, otherwise RRR = 42%, 95% CI = 31% to 51%).
                     
                  </p>
                  <div class="table pos-float" id="T4">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="1655/T4.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="1655/T4.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 4.</strong> </span> 
                        <p id="p-38" class="first-child">Multiple-treatment meta-analysis showing hazard ratios (with 95% confidence intervals) for death for each type of regimen
                           as compared with monotherapy that involves neither platinum nor taxane (not ip)*
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-40">Monte Carlo simulations showed a 92% probablilty that combinations of platinum and taxane with intraperitoneal administration
                     were the most effective regimens, whereas there was a 6% probability that the best regimen was platinum-based combination
                     chemotherapy with intraperitoneal administration. Therefore, it was 98% likely that the most effective regimen included intraperitoneal
                     administration. The probability that any other type of regimen was the best for prolonging survival was less than 2%. Similar
                     results were seen also in a more simplified multiple-treatment meta-analysis that merged the nonplatinum–nontaxane monotherapy
                     and combination regimens in the same treatment category (Supplementary Table 4, available at: <a href="http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22">http://jncicancerspectrum.oxfordjournals.org/jnci/content/vol98/issue22</a>).
                  </p>
                  
                  <p id="p-41">According to the two-level random-effects model, no important incoherence between comparisons was detected (incoherence =
                     .001). Only one particular comparison loop showed incoherence. Specifically, in the direct comparison, platinum monotherapy
                     was marginally better than taxane monotherapy (HR = 0.87, 95% CI = 0.71 to 1.06), but it was much better based on indirect
                     evidence from the comparison of these two regimens against monotherapy with nonplatinum, nontaxane agents (HR = 0.53, 95%
                     CI = 0.36 to 0.80). The reason for this incoherence was that this comparison loop includes both trials with exclusively first-line
                     treatment and trials with patients on second-line treatment. The nonplatinum, nontaxane regimens for second-line treatment
                     included topotecan, which was not included in first-line therapy. Furthermore, hazard ratios estimated from direct analyses
                     limited to first-line treatments were not materially different from those estimated from analyses of both first- and second-line
                     therapies (<a id="xref-table-wrap-4-2" class="xref-table" href="#T4">Table 4</a>).
                  </p>
                  
                  <p id="p-42">Given the small number of trials assessing second-line treatment, the multiple-treatment meta-analysis method is unstable
                     and thus potentially unreliable for the analysis of second-line treatments. There was a suggestion that platinum and taxane–containing
                     combinations could result in a borderline statistically significant relative risk reduction of mortality against platinum
                     monotherapy (HR = 0.53, 95% CI = 0.29 to 0.96) and taxane monotherapy (HR = 0.47, 95% CI = 0.22 to 0.99). On direct comparison,
                     the hazard ratio for mortality of platinum and taxane–containing combinations versus platinum monotherapy was 0.82 (95% CI
                     = 0.69 to 0.97), while there was no direct comparison of the combination versus taxane monotherapy.
                  </p>
                  
                  
               </div>
               <div class="section" id="sec-10">
                  <div class="section-nav"><a href="#sec-5" title="RESULTS" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>D<span class="sc">ISCUSSION</span></h2>
                  
                  <p id="p-43">We examined 198 randomized trials that compared various chemotherapy regimens in women with ovarian cancer during the last
                     40 years. We show conclusively the major progress that has been achieved in prolonging the survival of these patients and
                     we have quantified the magnitude of the survival benefit. Compared with the early days, when neither platinum nor taxanes
                     were available and chemotherapy was clearly no better than supportive care for mortality outcomes <em>(<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>)</em>, median survival can now be more than doubled using currently available regimens. A platinum and taxane–based combination
                     with intraperitoneal administration <em>(<a id="xref-ref-18-2" class="xref-bibr" href="#ref-18">18</a>)</em> can reduce the risk of death by 55%. More than half (30%) of this benefit may be achieved with a standard platinum-based
                     combination. Taxanes without platinum do not appear to confer any clear survival benefit. Although the data pertain predominantly
                     to first-line treatment, the sparse data on second-line treatment are consistent with a superiority of combined platinum and
                     taxane regimens.
                  </p>
                  
                  <p id="p-44">The absolute magnitude of the increase in survival time is impressive. For an expected median survival of 2.5 years without
                     effective treatment, approximately 3 years are gained with the most effective current treatments. However, these benefits
                     should be tailored to the individual patient and balanced against tolerability. Multidrug combinations including both platinum
                     and taxanes can cause cumulative toxicities <em>(<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>,<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>)</em>. Intraperitoneal administration in particular has not been used in many centers around the world, and its implementation
                     may cause some challenges <em>(<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>)</em> and extra toxicities <em>(<a id="xref-ref-18-3" class="xref-bibr" href="#ref-18">18</a>)</em>. Platinum and taxane–based combinations with intraperitoneal administration are the best regimens for survival in our multiple-treatment
                     meta-analysis with very high probability; we estimate that some kind of intraperitoneal regimen is 98% likely to be the best.
                     However, if intraperitoneal administration proves difficult to implement, survival can still be almost doubled with a combination
                     of platinum and taxanes without intraperitoneal administration.
                  </p>
                  
                  <p id="p-45">The long-term evolution of cancer chemotherapy therapeutics creates difficulty in estimating the relative merits of regimens
                     that are introduced over a long period of successive steps. Newer regimens are unavoidably compared with previous regimens,
                     rather than to very old agents or no treatment. The multiple-treatment meta-analysis approach is attractive in this setting
                     because it can accommodate such successive steps through loops of indirect comparisons. Multiple-treatment meta-analysis can
                     prove a particularly useful approach to synthesize evidence on medical domains among which data on many treatments accumulate,
                     a scenario that is becoming relatively common in clinical therapeutics <em>(<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>)</em>. However, caution should be used for trials that are distant in time because of the potential danger of confounding with
                     other factors that vary over time, such as supportive or adjunct treatment practices <em>(<a id="xref-ref-34-1" class="xref-bibr" href="#ref-34">34</a>)</em>.
                  </p>
                  
                  <p id="p-46">We should also caution that a full evaluation of the possibility of incoherence for nine treatments would require up to 112
                     loops to be evaluated in the multiple-treatment meta-analysis framework. In our network, there were many treatment comparisons
                     for which no direct evidence was available and the evaluation of incoherence was impossible. Therefore, some conservative
                     interpretation is warranted, especially for treatments that have been involved in few trials. In this regard, more evidence
                     on regimens that include intraperitoneally administered agents, as well as longer term follow-up of the existing trials, would
                     be useful.
                  </p>
                  
                  <p id="p-47">Another possible limitation is that the current analysis is based on published group data, rather than individual-level information.
                     Therefore, we have included women across a wide range of prognoses, from stage I to advanced disease. However, the vast majority
                     of trials did not include any meaningful proportion of data for very early stage disease, a reflection of the fact that most
                     women with ovarian cancer are still diagnosed at relatively advanced stages. Individual-level information might allow a more
                     detailed appraisal of outcomes at different levels of risk <em>(<a id="xref-ref-35-1" class="xref-bibr" href="#ref-35">35</a>)</em>. Individual-level data would also be useful to address whether there is any effect modification by the type of surgical intervention,
                     stage, and whether residual tumor is left after surgery. In addition to depending on chemotherapy, optimization of outcomes
                     may depend also on the surgical approach. However, the power to detect effect modifications might still be limited, even with
                     individual-level information, in such a complex network of multiple treatments.
                  </p>
                  
                  <p id="p-48">It is also notable that, even though almost 40 000 women have participated in published randomized trials of chemotherapy
                     regimens in ovarian cancer, the large majority of investigations pertain to comparisons of similar types of treatment with
                     minor modifications in the dosing or schedule or minor differences in the compared drugs that belong to the same class of
                     agents. Although such trials may still help to improve our understanding of minor variants of different regimens, especially
                     regarding toxicity and tolerability, they are unlikely to result in major progress regarding improvement of survival. The
                     few exceptions of statistically significant survival differences that we have seen in such trials may be real but may also
                     simply reflect chance findings. With many investigators working in this field, it would be useful to design future trials
                     that will fill in important gaps where major loops of evidence have minimal or no information. An efficient strategic plan
                     for clinical research in the field would require infrastructure support. Moreover, there is a need for clinical trials cooperative
                     groups to develop complementary trials, to decrease duplication, and when appropriate, to also perform joint trials. The multiple-treatment
                     meta-analysis can offer an additional impetus to such an effort, and it may also be useful as new regimens, including molecularly
                     targeted treatments <em>(<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>)</em>, are developed.
                  </p>
                  
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-10" title="DISCUSSION" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-8">
                        
                        <p id="p-49">The authors have full responsibility for the study design, data collection and analysis, interpretation of the results, and
                           the preparation of and decision to submit the manuscript.
                        </p>
                        
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2006. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">(1)</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference (1) in text"
                           id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.1"
                             data-doi="10.1016/S1470-2045(02)00846-X">
                           <div class="cit-metadata"><cite>Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. <span class="cit-source">Lancet Oncol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">3</span>:<span class="cit-fpage">529</span>–36.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(02)00846-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12217790&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000177894600020&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(2)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.22.1655.2"
                             data-doi="10.3322/canjclin.51.1.15">
                           <div class="cit-metadata"><cite>Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. <span class="cit-source">CA Cancer J Clin</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">51</span>:<span class="cit-fpage">15</span>–36.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.3322/canjclin.51.1.15&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11577478&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000166879300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(3)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.22.1655.3">
                           <div class="cit-metadata"><cite>American Cancer Society. Cancer facts and figures: 2000. New York (NY): American Cancer Society; <span class="cit-pub-date">2000</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(4)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.22.1655.4"
                             data-doi="10.3322/canjclin.55.1.10">
                           <div class="cit-metadata"><cite>Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005 [erratum in CA Cancer J Clin 2005;55:259].
                                 <span class="cit-source">CA Cancer J Clin</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">55</span>:<span class="cit-fpage">10</span>–30.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.3322/canjclin.55.1.10&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15661684&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000231483900007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(5)</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference (5) in text"
                           id="ref-5">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.5">
                           <div class="cit-metadata"><cite>Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales <span class="cit-pub-date">1950</span>–1999. National Statistics SMPS No. 66. Available at: <a href="http://www.statistics.gov.uk/downloads/theme_health/cancertrends_5099.pdf">http://www.statistics.gov.uk/downloads/theme_health/cancertrends_5099.pdf</a>. [Last accessed: October 5, 2006.]</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(6)</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference (6) in text"
                           id="ref-6">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.6"
                             data-doi="10.1056/NEJMra041842">
                           <div class="cit-metadata"><cite>Cannistra SA. Cancer of the ovary. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">351</span>:<span class="cit-fpage">2519</span>–29.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMra041842&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15590954&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000225593100007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(7)</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference (7) in text"
                           id="ref-7">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.7"
                             data-doi="10.1056/NEJM199601043340101">
                           <div class="cit-metadata"><cite>McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel
                                 and cisplatin in patients with stage III and stage IV ovarian cancer. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">334</span>:<span class="cit-fpage">1</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM199601043340101&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7494563&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996TM48200001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(8)</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference (8) in text"
                           id="ref-8">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.8"
                             data-doi="10.1200/JCO.20.5.1248">
                           <div class="cit-metadata"><cite>Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced
                                 ovarian carcinoma during the platinum era: a meta-analysis. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">20</span>:<span class="cit-fpage">1248</span>–59.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=20/5/1248"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(9)</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference (9) in text"
                           id="ref-9">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.9"
                             data-doi="10.1038/bjc.1998.710">
                           <div class="cit-metadata"><cite>Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual
                                 patient data from 37 randomized trials. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">78</span>:<span class="cit-fpage">1479</span>–87.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/bjc.1998.710&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9836481&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077015900014&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(10)</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference (10) in text"
                           id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.10"
                             data-doi="10.1136/bmj.303.6807.884">
                           <div class="cit-metadata"><cite>Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials.
                                 <span class="cit-source">BMJ</span> <span class="cit-pub-date">1991</span>;<span class="cit-vol">303</span>:<span class="cit-fpage">884</span>–93.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=303/6807/884"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(11)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.22.1655.11">
                           <div class="cit-metadata"><cite>Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy
                                 of ovarian carcinoma: a meta-analysis. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1991</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">1668</span>–74.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=9/9/1668"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(12)</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference (12) in text"
                           id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.12">
                           <div class="cit-metadata"><cite>A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">13</span>:<span class="cit-fpage">726</span>–32.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=13/3/726"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(13)</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference (13) in text"
                           id="ref-13">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.13"
                             data-doi="10.1093/jnci/92.9.699">
                           <div class="cit-metadata"><cite>Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel
                                 versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year result. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">92</span>:<span class="cit-fpage">699</span>–708.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=92/9/699"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(14)</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference (14) in text"
                           id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.14">
                           <div class="cit-metadata"><cite>Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel
                                 versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study.
                                 <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">106</span>–15.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=18/1/106"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(15)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.22.1655.15"
                             data-doi="10.1200/JCO.2003.02.153">
                           <div class="cit-metadata"><cite>Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel
                                 compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">3194</span>–200.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=21/17/3194"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(16)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-98.22.1655.16"
                             data-doi="10.1093/jnci/djg036">
                           <div class="cit-metadata"><cite>du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel vs carboplatin/paclitaxel
                                 as first-line treatment of ovarian cancer. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">95</span>:<span class="cit-fpage">1320</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=95/17/1320"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(17)</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference (17) in text"
                           id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.17">
                           <div class="cit-metadata"><cite>Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin
                                 versus paclitaxel and carboplatin in advanced ovarian cancer. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">3084</span>–92.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=18/17/3084"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(18)</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference (18) in text"
                           id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.18"
                             data-doi="10.1056/NEJMoa052985">
                           <div class="cit-metadata"><cite>Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
                                 <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">2006</span>;<span class="cit-vol">354</span>:<span class="cit-fpage">34</span>–43.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa052985&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16394300&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000234358600006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(19)</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference (19) in text"
                           id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.19"
                             data-doi="10.1136/bmj.331.7521.897">
                           <div class="cit-metadata"><cite>Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence.
                                 <span class="cit-source">BMJ</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">331</span>:<span class="cit-fpage">897</span>–900.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=331/7521/897"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(20)</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference (20) in text"
                           id="ref-20">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.20"
                             data-doi="10.1002/sim.1201">
                           <div class="cit-metadata"><cite>Lumley T. Network meta-analysis for indirect treatment comparisons. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">2313</span>–24.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1201&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12210616&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000177458600002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(21)</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference (21) in text"
                           id="ref-21">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.21"
                             data-doi="10.1001/jama.289.19.2534">
                           <div class="cit-metadata"><cite>Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive
                                 therapies used as first-line agents: a network meta-analysis. <span class="cit-source">JAMA</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">289</span>:<span class="cit-fpage">2534</span>–44.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1001/jama.289.19.2534&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12759325&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000182976500022&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(22)</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference (22) in text"
                           id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.22">
                           <div class="cit-metadata unstructured">Cochrane Collaboration. Authors' handbook. Available at: <a href="http://www.cochrane.org">http://www.cochrane.org</a>. [Last accessed: October 5, 2006.]
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(23)</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference (23) in text"
                           id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.23"
                             data-doi="10.1002/sim.1191">
                           <div class="cit-metadata"><cite>Hopewell S, Clarke M, Lusher A, Lefebvre C, Westby M. A comparison of handsearching versus MEDLINE searching to identify reports
                                 of randomized controlled trials. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">1625</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1191&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111923&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900009&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(24)</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference (24) in text"
                           id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.24"
                             data-doi="10.1002/(SICI)1097-0258(19981230)17:24&lt;2815::AID-SIM110&gt;3.0.CO;2-8">
                           <div class="cit-metadata"><cite>Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival
                                 endpoints. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">2815</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9921604&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077527600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(25)</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference (25) in text"
                           id="ref-25">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.25"
                             data-doi="10.7326/0003-4819-127-9-199711010-00008">
                           <div class="cit-metadata"><cite>Lau J, Ioannidis, Schmid CH. Quantitative synthesis in systematic reviews. <span class="cit-source">Ann Intern Med</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">127</span>:<span class="cit-fpage">820</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.7326/0003-4819-127-9-199711010-00008&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9382404&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997YD89800007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(26)</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference (26) in text"
                           id="ref-26">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.26"
                             data-doi="10.1002/sim.1186">
                           <div class="cit-metadata"><cite>Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">1539</span>–58.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1186&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111919&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(27)</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference (27) in text"
                           id="ref-27">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.27">
                           <div class="cit-metadata"><cite>Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. Indirect comparisons of competing interventions.
                                 <span class="cit-source">Health Technol Assess</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">1</span>-iv.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=16303099&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(28)</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference (28) in text"
                           id="ref-28">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.28"
                             data-doi="10.1002/sim.1875">
                           <div class="cit-metadata"><cite>Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">23</span>:<span class="cit-fpage">3105</span>–24.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1875&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15449338&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000224307300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(29)</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference (29) in text"
                           id="ref-29">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.29"
                             data-doi="10.1186/1471-2288-2-13">
                           <div class="cit-metadata"><cite>Baker SG, Kramer BS. The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better
                                 than C? <span class="cit-source">BMC Med Res Methodol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">2</span>:<span class="cit-fpage">13</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1186/1471-2288-2-13&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12429069&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(30)</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference (30) in text"
                           id="ref-30">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.30">
                           <div class="cit-metadata"><cite>Lumley T, Keech A. Meta-meta-analysis with confidence. <span class="cit-source">Lancet</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">346</span>:<span class="cit-fpage">576</span>–7.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7658798&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RQ98600044&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(31)</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference (31) in text"
                           id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.31"
                             data-doi="10.1158/1078-0432.CCR-04-0683">
                           <div class="cit-metadata"><cite>Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? <span class="cit-source">Clin Cancer Res</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">10</span>:<span class="cit-fpage">7439</span>–49.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=10/22/7439"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(32)</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference (32) in text"
                           id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.32"
                             data-doi="10.1016/S0140-6736(98)04119-1">
                           <div class="cit-metadata"><cite>ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin,
                                 and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. <span class="cit-source">Lancet</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">352</span>:<span class="cit-fpage">1571</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(98)04119-1&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9843101&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000076998900008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(33)</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference (33) in text"
                           id="ref-33">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.33"
                             data-doi="10.1111/j.1525-1438.2005.15304.x">
                           <div class="cit-metadata"><cite>Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E, Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in
                                 combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube.
                                 <span class="cit-source">Int J Gynecol Cancer</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">426</span>–31.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1111/j.1525-1438.2005.15304.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15882165&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000228979300003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(34)</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference (34) in text"
                           id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.34"
                             data-doi="10.1016/S0895-4356(00)00311-5">
                           <div class="cit-metadata"><cite>Trikalinos TA, Ioannidis JP. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient
                                 data. <span class="cit-source">J Clin Epidemiol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">54</span>:<span class="cit-fpage">245</span>–52.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0895-4356(00)00311-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11223322&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000167162300005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(35)</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference (35) in text"
                           id="ref-35">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.35"
                             data-doi="10.1016/S0140-6736(06)69615-3">
                           <div class="cit-metadata"><cite>Ioannidis JPA. Indirect comparisons: the mesh and mess of clinical trials. <span class="cit-source">Lancet</span> <span class="cit-pub-date">2006</span>;<span class="cit-vol">368</span>:<span class="cit-fpage">1470</span>–2.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(06)69615-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17071265&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000241582700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(36)</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference (36) in text"
                           id="ref-36">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.36"
                             data-doi="10.1586/14737140.5.5.855">
                           <div class="cit-metadata"><cite>Muggia F, Kosloff R. Investigational agents for epithelial ovarian cancer. <span class="cit-source">Expert Rev Anticancer Ther</span> <span class="cit-pub-date">2005</span>;<span class="cit-vol">5</span>:<span class="cit-fpage">855</span>–68.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1586/14737140.5.5.855&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16221055&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000240921900015&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(37)</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference (37) in text"
                           id="ref-37">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-98.22.1655.37"
                             data-doi="10.1038/nature04296">
                           <div class="cit-metadata"><cite>Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted
                                 therapies. <span class="cit-source">Nature</span> <span class="cit-pub-date">2006</span>;<span class="cit-vol">439</span>:<span class="cit-fpage">353</span>–7.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/nature04296&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16273092&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000234682100049&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/98/22/1647.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/98/22/1664.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/98/22.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (15 November 2006) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    98
                                    </span><span class="slug-issue">
                                    (22):
                                    </span><span class="slug-pages">
                                    1655-1663.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djj443" class="slug-doi">10.1093/jnci/djj443</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/98/22/1655.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/98/22/1655.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/98/22/1655/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplementary-data">Supplementary Data</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=ARTICLES&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;98/22/1655" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B98%2F22%2F1655&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/98/22/1655.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=98/22/1655&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/98/22/1655.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3B98%2F22%2F1655&amp;citation=Kyrgiou%20et%20al.%2098%20%2822%29:%201655&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B98%2F22%2F1655&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=17105988&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B98%2F22%2F1655">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B98%2F22%2F1655">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Survival%20Benefits%20With%20Diverse%20Chemotherapy%20Regimens%20for%20Ovarian%20Cancer%3A%20Meta-analysis%20of%20Multiple%20Treatments%3A%20&amp;publicationDate=15%20November%202006&amp;author=Maria%20Kyrgiou%2C%20Georgia%20Salanti%2C%20Nicholas%20Pavlidis%2C%20Evangelos%20Paraskevaidis%2C%20John%20P.%20A.%20Ioannidis&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjj443&amp;volumeNum=98&amp;issueNum=22&amp;startPage=1655&amp;endPage=1663&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/98/22/1655.full?cited-by=yes&amp;legid=jnci;98/22/1655#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/98/22/1655" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/98/22/1655?access_num=/jnci/98/22/1655"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F98%2F22%2F1655&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/98/22/1655.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AKyrgiou%20author%3AM.%22"
                              class="cb-art-gs-auth author-link">Articles by  Kyrgiou, M.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AIoannidis%20author%3AJ.P.A.%22"
                              class="cb-art-gs-auth author-link">Articles by  Ioannidis, J. P. A.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/98/22/1655.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=17105988&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Kyrgiou%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Kyrgiou, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Salanti%20G&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Salanti, G.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Pavlidis%20N&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Pavlidis, N.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Paraskevaidis%20E&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Paraskevaidis, E.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Ioannidis%20JP&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Ioannidis, J. P. A.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="/content/98/22/1655.full?related-urls=yes&amp;legid=jnci;98/22/1655#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B98%2F22%2F1655&amp;current-view-path=/content/98/22/1655.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/22/1655&amp;title=Survival%20Benefits%20With%20Diverse%20Chemotherapy%20Regimens%20for%20Ovarian%20Cancer%3A%20Meta-analysis%20of%20Multiple%20Treatments+--+Kyrgiou%20et%20al.%2098%20%2822%29%3A%201655+--+&amp;doi=10.1093/jnci/djj443&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/22/1655&amp;title=Survival%20Benefits%20With%20Diverse%20Chemotherapy%20Regimens%20for%20Ovarian%20Cancer%3A%20Meta-analysis%20of%20Multiple%20Treatments+--+Kyrgiou%20et%20al.%2098%20%2822%29%3A%201655+--+&amp;doi=10.1093/jnci/djj443&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/98/22/1655&amp;title=Survival%20Benefits%20With%20Diverse%20Chemotherapy%20Regimens%20for%20Ovarian%20Cancer%3A%20Meta-analysis%20of%20Multiple%20Treatments+--+Kyrgiou%20et%20al.%2098%20%2822%29%3A%201655+--+&amp;doi=10.1093/jnci/djj443&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/22/1655&amp;title=Survival%20Benefits%20With%20Diverse%20Chemotherapy%20Regimens%20for%20Ovarian%20Cancer%3A%20Meta-analysis%20of%20Multiple%20Treatments+--+Kyrgiou%20et%20al.%2098%20%2822%29%3A%201655+--+&amp;doi=10.1093/jnci/djj443&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/22/1655&amp;title=Survival%20Benefits%20With%20Diverse%20Chemotherapy%20Regimens%20for%20Ovarian%20Cancer%3A%20Meta-analysis%20of%20Multiple%20Treatments+--+Kyrgiou%20et%20al.%2098%20%2822%29%3A%201655+--+&amp;doi=10.1093/jnci/djj443&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/98/22/1655&amp;title=Survival%20Benefits%20With%20Diverse%20Chemotherapy%20Regimens%20for%20Ovarian%20Cancer%3A%20Meta-analysis%20of%20Multiple%20Treatments+--+Kyrgiou%20et%20al.%2098%20%2822%29%3A%201655+--+&amp;doi=10.1093/jnci/djj443&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">M<span class="sc">ETHODS</span></a></li>
                        <li><a href="#sec-5">R<span class="sc">ESULTS</span></a></li>
                        <li><a href="#sec-10">D<span class="sc">ISCUSSION</span></a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/98/22/1655.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/98/22/1655.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>